- STATE-OF-THE-ART FACILIY ENABLES GROWTH OF ADME-TOX SERVICES
- FASTER TURNAROUND TIMES THROUGH ADDED CAPACITY & AUTOMATION
- OPENING EVENT PLANNED FOR APRIL 2023
Hamburg, Germany, 15 February 2023:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Cyprotex US, LLC, the US site of Cyprotex a wholly owned subsidiary of Evotec, has completed its relocation from Watertown, MA to a new state-of-the-art facility in Framingham, MA, paving the way for significant further growth of its ADME-Tox services business for US-based customers.
Since the acquisition by Evotec in 2016, Cyprotex US, LLC, world leader in predictive toxicology and ADME research, has been growing its US business through partnerships with Pharma and biotech companies. The relocation of the US site to Framingham goes along with upgrades to the latest liquid handling automation and mass spectrometry technology, translating to significant efficiency gains, higher capacity, and faster turnaround times and will mirror many of the assays offered at the Alderley Park, UK site of Cyprotex Discovery Ltd.
Further, Cyprotex’ customers and partners will stand to benefit from additional specialist services e.g. a full suite of transporter assays and a high-throughput transcriptomics offering for predicting drug-induced toxicity, which Cyprotex performs together with its parent company Evotec. With 30,000 square feet, Cyprotex’ new facility at 200 Staples Drive provides a high-throughput alternative for its partners on their doorstep. An opening event with clients will be held in April.
Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: “Integrating predictive toxicology and ADME research into the R&D continuum is a priority for the cost-efficient development of new medicines. Cyprotex’ expansion into a first-class scientific facility in Framingham will benefit both existing and new clients across the US. The co-location of Cyprotex’ offering in proximity to Evotec’s US East Coast sites, especially the sample management facility in Branford, CT, further allows us to drastically reduce turnaround times.”